Jaguar Health, Inc. Announces Special Meeting of Stockholders to Vote on Reverse Stock Split and Share Issuance

TL;DR

<b>Jaguar Health, Inc. will hold a Special Meeting on April 9, 2024, to vote on a reverse stock split and the issuance of shares related to preferred stock, aiming to comply with Nasdaq rules.</b>

AI Summary

Jaguar Health, Inc. (JAGX) filed a Proxy Statement (DEF 14A) with the SEC on March 15, 2024. Jaguar Health, Inc. is holding a Special Meeting of Stockholders on April 9, 2024. The meeting will include a vote to approve a reverse stock split of common stock, with a ratio between 1-for-2 and 1-for-150. Stockholders will also vote on the issuance of common stock upon exchange of Series J Perpetual Preferred Stock to accredited investors. This issuance is to comply with Nasdaq Listing Rule 5635(d). The company is seeking approval for the issuance of 18,837,500 shares of Common Stock pursuant to exchange agreements dated February 27, 2024.

Why It Matters

For investors and stakeholders tracking Jaguar Health, Inc., this filing contains several important signals. The proposed reverse stock split aims to increase the per-share market price of the Company's common stock, potentially improving its compliance with Nasdaq's minimum bid price requirement. Approving the share issuance is necessary to satisfy Nasdaq Listing Rule 5635(d), which requires stockholder approval for issuances that could result in a change of control or a significant dilution of existing shareholders.

Risk Assessment

Risk Level: medium — Jaguar Health, Inc. shows moderate risk based on this filing. The company is seeking approval for a reverse stock split and share issuance, which are common strategies to address potential delisting from Nasdaq due to low stock price, but these actions can also signal underlying financial distress or dilute existing shareholders.

Analyst Insight

Stockholders should carefully consider the implications of the proposed reverse stock split and share issuance on their investment, including potential dilution and the company's ability to regain compliance with Nasdaq listing standards.

Key Numbers

• April 9, 2024 — Special Meeting Date (Date of the Special Meeting of Stockholders.)
• 1-for-2 to 1-for-150 — Reverse Stock Split Ratio Range (The potential range for the reverse stock split.)
• 18,837,500 — Shares to be Issued (Number of common shares to be issued upon exchange of preferred stock.)
• February 27, 2024 — Exchange Agreement Date (Date of the agreements for the share issuance.)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant and filer of the proxy statement.
• April 9, 2024 (date) — Date of the Special Meeting of Stockholders.
• 1-for-2 to 1-for-150 (dollar_amount) — Range for the potential reverse stock split ratio.
• Series J Perpetual Preferred Stock (company) — Type of preferred stock involved in the share issuance.
• Nasdaq Listing Rule 5635(d) (regulator) — Rule requiring stockholder approval for certain share issuances.
• 18,837,500 (dollar_amount) — Number of shares of Common Stock to be issued.
• February 27, 2024 (date) — Date of the exchange agreements.
• 200 Pine Street, Suite 400, San Francisco, CA 94104 (company) — Company's business and mailing address.

FAQ

Risk Factors

• Compliance with Nasdaq Listing Rules [medium — regulatory]: The company may need to implement a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.
• Dilution from Share Issuance [medium — financial]: The issuance of 18,837,500 shares of common stock could significantly dilute existing shareholders' ownership.
• Effectiveness of Reverse Stock Split [low — operational]: There is no guarantee that a reverse stock split will successfully increase the stock price or maintain compliance with Nasdaq rules.

Key Financial Figures

• $0.0001 — standing voting common stock, par value $0.0001 per share (the "Common Stock") at a rat
• $6,500 — LC to solicit proxies for a base fee of $6,500 plus reimbursement of reasonable out-of

Filing Documents

• tm243532-2_def14a.htm (DEF 14A) — 254KB
• lg_jaguarhealth-4c.jpg (GRAPHIC) — 33KB
• sg_lisaaconte-bw.jpg (GRAPHIC) — 12KB
• px_jaguarproxy1pg01-bw.jpg (GRAPHIC) — 187KB
• px_jaguarproxy1pg02-bw.jpg (GRAPHIC) — 297KB
• px_jaguarproxy1pg03-bw.jpg (GRAPHIC) — 380KB
• 0001104659-24-034769.txt (&nbsp;) — 1426KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information regarding the beneficial ownership of shares of our Common Stock and Series J Preferred Stock as of March 1, 2024 for: each person known to us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock; each of our named executive officers; each of our directors; and all directors and named executive officers as a group. Information with respect to beneficial ownership has been furnished by each director, executive officer or beneficial owner of more than 5% of our Common Stock. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting and investment power with respect to the securities. Except as otherwise provided by footnote, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them. The number of shares of Common Stock used to calculate the percentage ownership of each listed person includes the shares of Common Stock underlying options or warrants or convertible securities held by such persons that are currently exercisable or convertible or exercisable or convertible within 60 days of March 1, 2024, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Percentage of beneficial ownership of Common Stock is based on (i) 206,757,242 shares of Common Stock and (ii) 2,014,131 shares of non-voting common stock that have no voting ri

View Full Filing

View this DEF 14A filing on SEC EDGAR